Last reviewed 2026-05-28 · How we verify

Phoslax

Dr. Rachel Holden · Phase 1 active Small molecule ✓ Verified May 2026

Phoslax is a Small molecule drug developed by Dr. Rachel Holden. It is currently in Phase 1 development. Also known as: Sodium Phosphate.

Phoslax is being studied in a clinical trial for its effect on oral phosphate tolerance in individuals with varying levels of kidney function. The trial, titled "Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate," is being conducted at Queen's University.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Phoslax
Also known as	Sodium Phosphate
Sponsor	Dr. Rachel Holden
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phoslax CI brief — competitive landscape report
Phoslax updates RSS · CI watch RSS
Dr. Rachel Holden portfolio CI

Frequently asked questions about Phoslax

What is Phoslax?

Phoslax is a Small molecule drug developed by Dr. Rachel Holden.

Who makes Phoslax?

Phoslax is developed by Dr. Rachel Holden (see full Dr. Rachel Holden pipeline at /company/dr-rachel-holden).

Is Phoslax also known as anything else?

Phoslax is also known as Sodium Phosphate.

What development phase is Phoslax in?

Phoslax is in Phase 1.

Manufacturer: Dr. Rachel Holden — full pipeline
Therapeutic area: All drugs in Other
Also known as: Sodium Phosphate

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing